Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy
Pfizer
AUGUST 3, 2022
Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy. Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy. Decision follows results of interim futility analysis which indicate Phase 3 REALM-DCM trial unlikely to meet primary endpoint.
Let's personalize your content